← 홈

Antibody

163개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 163개
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-CD30 mAb (SGN-30, SGN-30 (anti-CD30 mAb))

Anaplastic Large-Cell Lymphoma · CD30

#CD30#Antibody#Phase2#항체#면역항체+3
효능 ORR 89.5%임상시험 31상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
AntibodyRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
AntibodystaleBiogenPhase 2

90-Y-ibritumomab tiuxetan (90-Y-ibritumomab tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 30상태 ACTIVE
AntibodyRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 RECRUITING
AntibodystaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 DISCONTINUED
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 94.1%임상시험 30상태 RECRUITING
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 1)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 7%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 2)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 37.8%임상시험 30상태 RECRUITING
AntibodystaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 84.4%임상시험 30상태 ACTIVE
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Daratumumab/rHuPH20)

Multiple Myeloma; Non-Hodgkin Lymphoma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+3
효능 ORR 39.4%임상시험 24상태 ACTIVE
AntibodystaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

Rituximab and Hyaluronidase Human (Rituximab and Hyaluronidase Human)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 9%임상시험 18상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 67%임상시험 17상태 ACTIVE
AntibodystaleRochePhase 3

zanubrutinib, rituximab and lenalidomide (zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 45.7%임상시험 17상태 RECRUITING
AntibodystaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 16상태 ACTIVE

2 / 9 페이지

← 이전다음 →